Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Septerna, Inc.NASDAQ: SEPN
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income turns negative
Q3 FY2026 net income was -$26.59M, compared with $8.17M a year earlier. Trailing-twelve-month net income was -$59M. Over 3 fiscal years it compounded at +20.9% a year.
Context
- Net income amounted to 106.4% of revenue in FY2025, down 6572.5 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$47.03M (-3.8%) for the fiscal year ending Dec 2026, a step up from the -31.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$26.59M+104.0% QoQ
- Last fiscal yearDec 2025
- -$48.88M-31.9% YoY
- LTMSep 2026
- -$59M+0.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -425.3% | +107.0% | +532.4 pp |
| 1 year | -31.9% | -3.8% | +28.1 pp |
| 3-year CAGR | +20.9% | +32.0% | +11.1 pp |
| 5-year CAGR | +29.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (48.88M) USD
- Year-over-year change
- +31.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (48.88M) | +31.9% |
| FY2024 | 2024-12-31 | (71.8M) | -1817.7% |
| FY2023 | 2023-12-31 | 4.18M | +115.1% |
| FY2022 | 2022-12-31 | (27.68M) | — |
Net Income vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's LTM Sep 2026 net income of $59M is the 5th largest of the 7 companies compared; the peer median is $133.82M.
- Its year-over-year change of +0.3% is the 4th highest of 6, against a peer median of +62.6%.
- Net income amounts to 61.3% of revenue for SEPN, versus a peer median of 307.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $291.03M | +62.6% | +40.1% | — | |
KLRAKailera Therapeutics, Inc. | FY2025 | $148.96M | — | — | — |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $145.1M | +80.3% | +49.3% | — |
| LTM Mar 2026 | $122.54M | -335.9% | +4.5% | 612.7% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $59M | +0.3% | +20.9% | 61.3% |
| LTM Mar 2026 | $44.95M | -65.1% | -8.9% | — | |
| LTM Mar 2026 | $918K | +104.2% | +17.5% | 2.5% | |
| Peer median (excluding SEPN) | $133.82M | +62.6% | +17.5% | 307.6% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (27.68M) | 4.18M | (71.8M) | (48.88M) |
| Depreciation & Amortization | 577K | 848K | 1.4M | 1.6M |
| Deferred Income Tax | 0 | 491K | (491K) | 0 |
| Stock-Based Compensation | 1.52M | 1.62M | 3.15M | 8.48M |
| Change in Working Capital | 1.75M | 926K | 248K | 162.78M |
| Accounts Receivables | 0 | (151K) | (20K) | (10.19M) |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.73M | (653K) | 723K | 6.6M |
| Other Working Capital | 20K | 1.73M | (455K) | 166.36M |
| Other Non-Cash Items | 530K | (46.79M) | 18K | (13.79M) |
| Operating Cash Flow | (23.3M) | (38.72M) | (67.47M) | 110.19M |
| Capital Expenditures | (1.29M) | (2.88M) | (2.1M) | (518K) |
| Acquisitions (Net) | 0 | 0 | 0 | 12.5M |
| Purchases of Investments | 0 | 0 | (213.39M) | (450.95M) |
| Sales of Investments | 0 | 0 | 32.27M | 209.62M |
| Other Investing Activities | 0 | 25M | 22.63M | 0 |
| Investing Cash Flow | (1.29M) | 22.12M | (160.6M) | (229.35M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 82K | 0 | 302.79M | 1.69M |
| Common Stock Repurchased | 0 | (1K) | (1K) | (1K) |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 52K | 0 |
| Financing Cash Flow | 30.05M | 74.52M | 377.78M | 1.69M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.46M | 57.92M | 149.71M | (117.47M) |
| Free Cash Flow | (24.59M) | (41.6M) | (69.57M) | 109.67M |
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.